Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.

NCT07528898 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SHR-A1811
DRUG: Pertuzumab
DRUG: trastuzumab
DRUG: Chemotherapy

Sponsor

Hebei Medical University Fourth Hospital

Collaborators

[object Object]